Compare Gilead Sciences, Inc. (GILD) vs Monster Beverage Corp (MNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Monster Beverage Corp — how do they compare? Gilead Sciences, Inc. trades at $149.95 (market cap $182.40B), while Monster Beverage Corp trades at $43.51 (market cap $85.51B). The key difference: Gilead Sciences, Inc. is far larger — about 2.1× Monster Beverage Corp's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Monster Beverage Corp for 72 Days on average.
| GILD | MNST | |
|---|---|---|
Market Cap | $182.40B | $85.51B |
Volume | 4,469,821 | 8,569,709 |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $49.97 |
52-Week Low | $116.74 | $33.16 |
Typical Hold Time | 111 Days | 72 Days |
Enterprise Value | $205.46B | $83.81B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Monster Beverage (MNST) trades at $42.88, down 0.86% on the day, with a bearish technical signal from moving averages. The company reported strong fundamentals: Q2 2026 EPS of $0.30 beat estimates, revenue grew to $8.29 billion in 2025, and net income margin stands at 23.08%. A 1:2 stock split is scheduled for August 11, 2026. Analyst consensus is a 'Buy' with a $98.22 price target, but technical indicators show selling pressure near current levels.
The outlook for MNST is mixed: robust earnings growth and zero long-term debt support upside, but high valuation ratios (P/E of 40.42) and bearish technicals pose near-term risks. International expansion, particularly a 35% sales surge overseas, offers growth potential, though regulatory challenges in markets like India and inflation pressures could hinder performance. The stock's rich pricing requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
